Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism.
10.3858/emm.2011.43.4.025
- Author:
Jong Bae SEO
1
;
Sung Sik CHOE
;
Hyun Woo JEONG
;
Sang Wook PARK
;
Hyun Jung SHIN
;
Sun Mi CHOI
;
Jae Young PARK
;
Eun Wook CHOI
;
Jae Bum KIM
;
Dong Seung SEEN
;
Jae Yeon JEONG
;
Tae Gyu LEE
Author Information
1. R&D Center, BRN Science Co., Ltd., Biotechnology Incubating Center, Golden Helix, Seoul National University, Seoul 151-742, Korea. tglee@brnsci.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
adipocyte differentiation;
fatty acid oxidation;
fatty acid synthesis;
lipid metabolism;
Lysimachia foenum-graecum;
obesity
- MeSH:
3T3-L1 Cells;
Adipogenesis/*drug effects;
Adipose Tissue/drug effects/metabolism;
Adipose Tissue, White;
Animals;
Anti-Obesity Agents/administration & dosage/pharmacology/*therapeutic use;
Body Weight/drug effects;
CCAAT-Enhancer-Binding Protein-alpha/genetics;
Cell Differentiation/drug effects;
Eating/drug effects;
Fatty Acids/metabolism;
Gene Expression/drug effects;
Lipid Metabolism/*drug effects;
Lipids;
Lipogenesis/drug effects;
Mice;
Mice, Inbred C57BL;
Obesity/prevention & control;
PPAR gamma/antagonists & inhibitors/genetics;
Plant Extracts/*pharmacology;
Plants, Medicinal;
Primulaceae/*chemistry
- From:Experimental & Molecular Medicine
2011;43(4):205-215
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lysimachia foenum-graecum has been used as an oriental medicine with anti-inflammatory effect. The anti-obesity effect of L. foenum-graecum extract (LFE) was first discovered in our screening of natural product extract library against adipogenesis. To characterize its anti-obesity effects and to evaluate its potential as an anti-obesity drug, we performed various obesity-related experiments in vitro and in vivo. In adipogenesis assay, LFE blocked the differentiation of 3T3-L1 preadipocyte in a dose-dependent manner with an IC50 of 2.5 microg/ml. In addition, LFE suppressed the expression of lipogenic genes, while increasing the expression of lipolytic genes in vitro at 10 microg/ml and in vivo at 100 mg/kg/day. The anti-adipogenic and anti-lipogenic effect of LFE seems to be mediated by the inhibition of PPARgamma and C/EBPalpha expression as shown in in vitro and in vivo, and the suppression of PPARgamma activity in vitro. Moreover, LFE stimulated fatty acid oxidation in an AMPK-dependent manner. In high-fat diet (HFD)-induced obese mice (n = 8/group), oral administration of LFE at 30, 100, and 300 mg/kg/day decreased total body weight gain significantly in all doses tested. No difference in food intake was observed between vehicle- and LFE-treated HFD mice. The weight of white adipose tissues including abdominal subcutaneous, epididymal, and perirenal adipose tissue was reduced markedly in LFE-treated HFD mice in a dose-dependent manner. Treatment of LFE also greatly improved serum levels of obesity-related biomarkers such as glucose, triglycerides, and adipocytokines leptin, adiponectin, and resistin. All together, these results showed anti-obesity effects of LFE on adipogenesis and lipid metabolism in vitro and in vivo and raised a possibility of developing LFE as anti-obesity therapeutics.
